Comparison of Stool Microbiome in Children with Cystic Fibrosis Treated with and Without Elexacaftor-Tezacaftor-Ivacaftor-A Pilot Study. [PDF]
Sankararaman S +9 more
europepmc +1 more source
Elexacaftor/Tezacaftor/Ivacaftor in Children with Cystic Fibrosis: No Longer "If" but a Question of "When" to Start. [PDF]
Selvadurai H.
europepmc +1 more source
Elexacaftor-tezacaftor-ivacaftor enhances first-phase insulin secretion and improves glucose control in cystic fibrosis. [PDF]
Edlund A +3 more
europepmc +1 more source
Assessment of efficacy and tolerability of elexacaftor-tezacaftor-ivacaftor in an observational cohort study of "aged" people with cystic fibrosis. [PDF]
Blankenship S +6 more
europepmc +1 more source
Real-World Outcomes of Elexacaftor/Tezacaftor/Ivacaftor in Children with Cystic Fibrosis. [PDF]
Perrem L, McNally P.
europepmc +1 more source
Impact of Elexacaftor-Tezacaftor-Ivacaftor on Gastrointestinal Symptoms, Intestinal Ultrasound, and Pancreatic Stiffness in Cystic Fibrosis. [PDF]
Fraquelli M +5 more
europepmc +1 more source
Aging Gracefully: Does Elexacaftor/Tezacaftor/Ivacaftor Safety and Efficacy Stand the Test of Time? [PDF]
Wilson G, Hughes D.
europepmc +1 more source
Elexacaftor-tezacaftor-ivacaftor and cystic fibrosis liver disease: A turning point that calls for cautious optimism. [PDF]
Rautou PE +3 more
europepmc +1 more source
Evaluation of Elexacaftor/Tezacaftor/Ivacaftor-Mediated Drug-Induced Liver Injury Using a Liver-On-Chip Model. [PDF]
Shi A, Agarwal P, Liu ZX, Beringer PM.
europepmc +1 more source
The Changing Transplant Landscape in the Era of Elexacaftor/Tezacaftor/Ivacaftor: A Word of Caution. [PDF]
Semenchuk J +8 more
europepmc +1 more source

